BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27726427)

  • 1. The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer.
    Sheikhbahaei S; Mena E; Yanamadala A; Reddy S; Solnes LB; Wachsmann J; Subramaniam RM
    AJR Am J Roentgenol; 2017 Feb; 208(2):420-433. PubMed ID: 27726427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
    Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
    J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung Cancer Recurrence:
    Kandathil A; Sibley RC; Subramaniam RM
    AJR Am J Roentgenol; 2019 Nov; 213(5):1136-1144. PubMed ID: 31361525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
    Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
    Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
    Tauhardt E; Reissig A; Winkens T; Freesmeyer M
    Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF; Quirce R; Martínez-Rodríguez I; Banzo I; Rubio-Vassallo AS; Del Castillo-Matos R; Ortega-Nava F; Martínez-Amador N; Ibáñez-Bravo S; Carril JM
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
    Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M
    Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.